Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease
In patients with MASLD, empagliflozin was associated with better clinical outcomes compared to dapagliflozin, particularly in reducing cardiovascular and renal events, hospitalizations, and mortality.
Authors
- Po‐Yu Huang (ORCID: https://orcid.org/0000-0002-8682-1322)
- Chih‐Cheng Lai (ORCID: https://orcid.org/0000-0002-6334-2388)
- Tsung Yu (ORCID: https://orcid.org/0000-0002-5773-3665)
- Wan‐Hsuan Hsu (ORCID: https://orcid.org/0000-0002-2517-1792)
- Mei‐Yuan Liu (ORCID: https://orcid.org/0000-0003-3760-1945)
- Ya‐Wen Tsai (ORCID: https://orcid.org/0000-0003-4630-3923)
- Jheng‐Yan Wu (ORCID: https://orcid.org/0000-0002-3290-1909)
- Ting-Hui Liu
- Kuang‐Ming Liao (ORCID: https://orcid.org/0000-0003-4364-8248)
- Min‐Hsiang Chuang (ORCID: https://orcid.org/0000-0002-8538-4861)
- Yan Tu (ORCID: https://orcid.org/0000-0003-1517-1198)
- Kuo-Chuan Hung (ORCID: https://orcid.org/0000-0002-4507-8085)
- Chia-Chih Kuo
Institutions
- National Sun Yat-sen University (TW)
- Chi Mei Medical Center (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3389/fendo.2025.1669613
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00